FDA APPROVAL OF ELEVIDYS

This webinar discusses a groundbreaking gene therapy treatment for Duchenne Muscular Dystrophy (DMD), focusing on a method to introduce a miniaturized version of the dystrophin gene using a viral vector. This therapy, while not a cure, aims to improve the quality of life for patients. The treatment involves a single dose, but patients must undergo extensive pre-treatment screening to help mitigate the chances severe immune reactions. Key points include understanding the genetic mutation specifics, managing potential side effects, and adhering to post-treatment protocols. The process includes genetic testing, antibody screening, and regular follow-ups. This therapy has been approved for use in the US, with ongoing studies to confirm its long-term efficacy.

Watch HERE

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate